JP Morgan Chase
RGC icon

JP Morgan Chase’s Regencell Bioscience RGC Stock Holding History

JP Morgan Chase’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.7K Buy
+845
New +$23.9K ﹤0.01% 6545

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VA
Vident Advisory Alpharetta, Georgia $11.7B AUM 37.32% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

JP Morgan Chase's RGC Position: Q1 2026 in Review

JP Morgan Chase opened a new position in Regencell Bioscience (RGC) in Q1 2026: 845 shares worth $19.7K. The stake represents ﹤0.01% of the portfolio and ranks #6545 among its holdings.

31 funds tracked by Wall St. Rank hold RGC as of Q1 2026.

  • JP Morgan Chase held 845 shares of Regencell Bioscience worth $19.7K as of Q1 2026.
  • Regencell Bioscience was a new JP Morgan Chase position in Q1 2026.
  • Regencell Bioscience made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6545 holding.
  • 31 funds tracked by Wall St. Rank held Regencell Bioscience as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.